Merckle Gmbh

Ludwig Merckle K.g., Chem. Pharm. Fabrik

Other

Gunter Metz

Manfred Specker

Kurt Rauchle

Manfred Erdmann

By using a new method 2-(2-hydroxyethoxy)-ethanol ester is produced from flufenamic acid as a result of direct esterification with diol with an excess of 8-15 mol diol per mol flufenamic acid without concurrent removal of water.

Method of producing 2-(2-hydroxyethoxy)-ethanol ester of flufenamic acid

Novel diethylene glycol monoester of antirheumatically effective acids, e.g., lonazolac and diclofenac and others are disclosed which have inflammation inhibitory properties superior to the corresponding acid base forms. They may be produced through direct esterification without elimination of water and are suitable in the fight against diseases of the rheumatic complex.

Diethylene glycol monoester derivatives, compositions and therapeutic use

The invention relates to the use of naproxen lysinate, ketoprofen lysinate and/or diclofenac lysinate in the form of an injectable solution in the treatment of inflammations and rheumatic disorders, and to injectable solutions containing the anti-inflammatory active compound naproxen, ketoprofen or diclofenac in the form of its lysinate.

Injectable solution for the treatment of inflammations

At least one barbiturate or one of its pharmaceutically acceptable salts is combined with cinnarizine or flunarizine or one of their pharmaceutically acceptable salts to provide a hypnotic requiring lower dosages of barbiturates to produce the same effect as the barbiturate alone.

Pharmaceutical for the treatment of sleep disorders

The object of the present invention are novel aminobenzoic acid derivatives having the general formula: ##STR1## wherein R.sub.1 is hydrogen, chlorine, hydroxy, acetoxy or C.sub.1 -C.sub.3 -alkoxy;

Aminobenzoic acid derivatives

The use of etofylline clofibrate for the treatment of elevated serum levels of uric acid in humans is disclosed.

Treatment of hyperuricaemia with etofylline clofibrate

The use of the combination of clofibrinic acid or clofibrate with cinnarizine for the treatment of hypertension in humans is disclosed.

Treatment of hypertension with combination of clofibrinic acid or

There are disclosed N-acyl substituted benzamides of the general formula: ##STR1## wherein: X is carbon or nitrogen;

Growing community of inventors

Blaubeuren, Germany

Gunter Metz